Historically, PBSC mobilization strategies have consisted of chemotherapy and/or cytokines; these regimens are limited by chemotherapy-induced adverse events and a mobilization failure rate of up to 30%. 1 Mobilization failure following cytokines with or without chemotherapy may be due to multiple factors including previous mobilization failure, 2, 3 46 months from prior therapy to the start of mobilization, 3 prior therapy (for example, radiotherapy, melphalan, platinum-containing chemotherapy regimens, lenalidomide, fludarabine), [2] [3] [4] low premobilization platelet counts 2, 3 and low WBC counts. 3, 5 Thrombocytopenia (platelets p150 Â 10 9 /L) at the time of mobilization was consistently predictive of mobilization failure by univariate and multivariate analyses when examined in association with chemotherapy-based mobilization strategies. 2, 3 Whether these trends hold true for patients who receive G-CSF plus plerixafor (a CXCR4 chemokine receptor antagonist), a recent addition to the therapeutic armamentarium, remains to be seen. 6 Phase 3 studies demonstrated a significant improvement in mobilization outcomes with G-CSF combined with plerixafor, compared with G-CSF alone, 1, 7 in non-Hodgkin's lymphoma (NHL) and multiple myeloma patients. However, patients in the phase 3 studies were excluded if the platelet count was o100 Â 10 9 /L and the WBC was o2.5 Â 10 9 /L. 1, 7 This is a brief report on evaluating the efficacy of plerixafor plus G-CSF in patients with thrombocytopenia or low WBC. In this retrospective analysis of patients with NHL or multiple myeloma in the plerixafor compassionate use program (CUP) in the United States, 8, 9 the efficacy of G-CSF plus plerixafor mobilization was examined in patients who had failed prior mobilization and showed varying degrees of thrombocytopenia (platelets o85, o100 or 100 À 150 Â 10 9 /L) or leukopenia (WBC o2.5 Â 10 9 /L). Eligibility criteria were previously reported, 8, 9 including requiring minimum WBC counts 42.5 Â 10 9 /L, absolute neutrophil counts 41.5 Â 10 9 /L and platelet counts 4100 Â 10 9 /L. Some patients with platelet counts o85 Â 10 9 /L or low WBC counts received waivers for participation and were included in this analysis.
Following a rest period of X7 days from prior mobilization attempts, the mobilization regimen consisted of G-CSF 10 mg/kg/day subcutaneously (s.c.) alone for days 1-4 plus plerixafor 0.24 mg/kg s.c. (0.16 mg/kg if creatinine clearance o50 mL/min) beginning on the evening of day 4 through day 8 (or until apheresis completion). Apheresis began on the morning of day 5 and continued for a total of four aphereses or until collection of X2 Â 10 6 CD34 þ cells/kg for auto-HSCT. Patients were required to provide X2 Â 10 6 CD34 þ cells/kg during apheresis in order to proceed to transplantation. Neutrophil engraftment was defined as the first of 3 consecutive days with neutrophil counts X0.5 Â 10 6 /L or the first day of X1.0 Â 10 6 /L. Platelet engraftment was defined as the first day of platelet counts X20 Â 10 6 /L without a need for platelet transfusion. Engraftment data were evaluated for patients who received only cells mobilized with G-CSF þ plerixafor and not pooled CD34 þ cells from prior mobilization procedures.
Of 833 patients in the CUP database, 223 NHL and multiple myeloma patients had thrombocytopenia (platelets p150 Â 10 9 /L) and 17 patients had leukopenia. Median age for all patients was 60 years, except for patients in the o85 Â 10 9 /L platelet group, who were slightly younger with a median age of 52 years.
At least 65% of patients in all groups, regardless of baseline platelet or WBC counts, achieved a median mobilization goal of X2 Â 10 6 CD34 þ cells/kg (Table 1 ). All but the normal platelet group achieved the minimal CD34 þ cell yield in a median of 2 apheresis days; patients with normal platelet counts achieved the collection goal faster, by 1.5 days (range, 1-7 days; Table 1 ). Regardless of platelet or WBC levels, 65-83% of patients attained the CD34 þ cell collection goal (Table 1) .
For all platelet groups, 61-65% of patients progressed to transplantation (Table 1) . Patients were transplanted with a median X2.69 Â 10 6 CD34 þ cells/kg in all platelet groups. Patients with low and normal WBC counts were transplanted with medians of 2.3 Â 10 6 and 3.4 Â 10 6 CD34 þ cells/kg, respectively. Engraftment times were similar among all groups, ranging from 11.0 to 12.0 days for neutrophil engraftment and 19.0 to 22.0 days for platelet engraftment.
Low platelet count (p150 Â 10 9 /L) before mobilization was consistently predictive of mobilization failure. Multivariate analysis identified BM involvement and low platelet count as two factors significantly predictive of mobilization failure in NHL patients who received intermediate-dose CY plus G-CSF. 5 Patients who had 200, 150 and 100 Â 10 9 /L platelets before mobilization showed increasing mobilization failure risks of 9%, 13% and 19%, respectively. When combined with the presence of BM involvement, the risk of failure escalated to 39%, 55% and 61%, respectively.
Plerixafor with G-CSF is effective for upfront mobilization, as well as for remobilization in patients who are predicted to fail or have failed prior mobilization attempts. 1, 7 Although thrombocytopenia is a risk factor for poor mobilization, this appears to be overcome by mobilization with G-CSF plus plerixafor. These data demonstrate that in high-risk thrombocytopenic patients, remobilization with plerixafor plus G-CSF allowed 61-65% of patients to yield the minimal CD34 þ cell number to proceed to transplantation, including patients with platelets o85 Â 10 9 /L. Compared with the initial CUP study report, in patients who had median 4135 Â 10 9 /L premobilization platelet counts and were 1 month from prior mobilization failure with chemotherapy and/or cytokines, these data show similar mobilization outcomes in patients with low premobilization platelet and/or WBC counts. 8 In NHL, multiple myeloma and Hodgkin's disease patients, 466% of patients achieved successful CD34 þ collection yield in a median of 3.5 days, with 75% of patients progressing to transplantation and with posttransplantation engraftment times of 11 days for neutrophils and 18 days for platelets. 8 Despite low premobilization platelet and/or WBC counts in the current analysis, patients showed similar mobilization and transplantation outcomes. In thrombocytopenic patients, 65-79% of patients mobilized X2 Â 10 6 CD34 þ cells/kg in a median of 2 apheresis days. Approximately two-thirds of these patients (61-64%) went on to transplantation, demonstrating median engraftment times of 12 days for neutrophils and 20-22 days for platelets.
These analyses demonstrate acceptable CD34 þ cell mobilization rates for patients who had failed prior mobilization strategies regardless of premobilization platelet or WBC levels, thus challenging the axiom that thrombocytopenia or leukopenia before mobilization is predictive of failure.
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